Hepatitis C in dialysis units: the Saudi experience

Area of Science:

• Hepatology
• Infectious Diseases
• Nephrology

Background:

• Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and liver cancer.
• Hemodialysis patients face elevated risks of HCV infection due to compromised immunity, comorbidities, and prolonged blood exposure.
• HCV transmission in dialysis units is a growing global concern, with prevalence varying significantly by region.

Purpose of the Study:

• To review the epidemiology and management of Hepatitis C virus (HCV) infection in hemodialysis patients.
• To highlight the specific challenges and risks associated with HCV in this vulnerable population.
• To discuss current and potential treatment strategies for HCV in hemodialysis patients.

Main Methods:

• Review of existing literature on HCV prevalence, transmission, and treatment in hemodialysis settings.
• Analysis of epidemiological data, including seroconversion rates and prevalent genotypes.
• Examination of infection control measures and therapeutic interventions.

Main Results:

• HCV prevalence in Saudi Arabia ranges from 15% to 80%, remaining around 50% recently.
• Genotype 4 is most common in Saudi Arabia, followed by genotypes 1a and 1b; genotypes 1 and 4 correlate with liver disease severity.
• Interferon-based therapies, with or without ribavirin, show promise for treating chronic HCV in dialysis patients.

Conclusions:

• HCV infection is a critical issue in hemodialysis units, necessitating stringent infection control protocols.
• Effective management requires isolation strategies, adherence to policies, and staff training.
• Antiviral therapies, particularly interferon-based regimens, offer viable treatment options for HCV-infected dialysis patients.